. Novartis said it is reviewing the complaints. The FDA has issued a warning to patients about a possible mix-up between powerful prescription pain drugs. The FDA said the warning is a result of major manufacturing problems at a. Lincoln, Nebraska, facility. The FDA said the problem is a result of major manufacturing problems at